Eli Lilly is on track to overtake pharma rivals and claim the industry’s top spot by late 2026, completing one of the most dramatic repositionings in Big Pharma’s recent history. Aggressive and base scenarios place Lilly’s rise to the number one slot in 2026, while a conservative prediction forecasts that the firm will do so… The post Lilly is set to lead pharma in 2026, but can it justify an $800B valuation? appeared first on Drug Discovery and Development.
